News | November 30, 2022
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Acquisition expands Merck’s growing hematology portfolio
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Subscribe To Our Newsletter & Stay Updated
